The acquisition centers on Landos' lead compound, an oral NLRX1 agonist currently in phase 2 clinical trials for ulcerative colitis and Crohn's disease
The Oncologic Drugs Advisory Committee voted in favor of expanding the use of J&J and Legend's Carvykti and Bristol Myers Squibb and 2seventy bio's Abecma